Brain Tumor Stem Cell Dependence on Glutaminase Reveals a Metabolic Vulnerability through the Amino Acid Deprivation Response Pathway

Abstract

Cancer cells can metabolize glutamine to replenish TCA cycle intermediates, leading to a dependence on glutaminolysis for cell survival. However, a mechanistic understanding of the role that glutamine metabolism has on the survival of glioblastoma (GBM) brain tumor stem cells (BTSC) has not yet been elucidated. Here we report that, across a panel of 19 glioblastoma BTSC lines, inhibition of glutaminase (GLS) showed a variable response from complete blockade of cell growth to absolute resistance. Surprisingly, BTSC sensitivity to GLS inhibition was a result of reduced intracellular glutamate triggering the amino acid deprivation response (AADR) and not due to the contribution of glutaminolysis to the TCA cycle. Moreover, BTSC sensitivity to GLS inhibition negatively correlated with expression of the astrocytic glutamate transporters EAAT1 and EAAT2. Blocking glutamate transport in BTSCs with high EAAT1/EAAT2 expression rendered cells susceptible to GLS inhibition, triggering the AADR and limiting cell growth. These findings uncover a unique metabolic vulnerability in BTSCs and support the therapeutic targeting of upstream activators and downstream effectors of the AADR pathway in GBM. Moreover, they demonstrate that gene expression patterns reflecting the cellular hierarchy of the tissue of origin can alter the metabolic requirements of the cancer stem cell population. Statement of Significance: Glioblastoma brain tumor stem cells with low astrocytic glutamate transporter expression are dependent on GLS to maintain intracellular glutamate to prevent the amino acid deprivation response and cell death. Research.

Effects of the Combined Treatment with a G-Quadruplex-Stabilizing Ligand and Photon Beams on Glioblastoma Stem-like Cells: A Magnetic Resonance Study

“…Its synthesis and degradation are part of the glutamate/glutamine cycle. Due to its role as a neurotransmitter, Glu is constantly released from neurons and its uptake by astrocytes at the neuronal synapse is essential for maintaining normal brain function [ 65 , 66 ]. After its release, Glu is taken up by astrocytes, where it is converted to Gln and released again [ 64 ].…”

Therapeutic Potential of Selenium in Glioblastoma

“…The dependency of glioblastoma and tumor-associated endothelial cells on glycolysis, but also glutaminolysis for energy production, opens further opportunities to reduce tumor-related angiogenesis (Seyfried et al, 2015;Artzi et al, 2017). Glutamine consumption is often increased in malignant tumors and the inhibition of intracellular glutaminase (GLS) activity -which converts glutamine into glutamate -has been shown to reduce proliferation and angiogenesis of tumor cells of different origin (Draoui et al, 2017;Zhao et al, 2017;Bruntz et al, 2019;Restall et al, 2020). Recent studies have demonstrated that Se-induced inhibition of glutaminolysis in malignant cells resulted from the suppression of GLS activity (Zhao et al, 2017;Bruntz et al, 2019).…”

Therapeutic Targeting of Glutaminolysis as a Novel Strategy to Combat Cancer Stem Cells

“…Compound 968 and CB-839 were able to successfully dampen the in vitro clonogenicity of glioblastoma stem-like cells (GSCs) in neurosphere colonies, resulting in a significant reduction in the number of GSCs [ 148 ]. Further investigation of the mechanism was performed by another study, which showed that the sensitivity to CB-839 in GSCs was not due to the contribution of glutaminolysis to the TCA cycle; rather, the sensitivity was brought on by reduced intracellular glutamate, which led to the amino acid deprivation response (AADR) [ 149 ]. Continuing this line of research, a modification of the CB-839 delivery route was developed by loading the drug into PEGylated gold nanoparticles with conjugated CD133 aptamers (Au-PEG-CD133-CB-839) [ 150 ].…”